These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 15661233

  • 1. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
    Olivier RI, Lubsen-Brandsma LA, van Boven H, van Beurden M.
    Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
    [Abstract] [Full Text] [Related]

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ.
    Br J Cancer; 2004 Apr 19; 90(8):1492-7. PubMed ID: 15083174
    [Abstract] [Full Text] [Related]

  • 4. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U.
    BJOG; 2011 Jun 19; 118(7):814-24. PubMed ID: 21392246
    [Abstract] [Full Text] [Related]

  • 5. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.
    Am J Obstet Gynecol; 2006 Jun 19; 194(6):1702-9. PubMed ID: 16731090
    [Abstract] [Full Text] [Related]

  • 6. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.
    N Engl J Med; 2002 May 23; 346(21):1609-15. PubMed ID: 12023992
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR.
    J Clin Oncol; 2000 Nov 01; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [Abstract] [Full Text] [Related]

  • 8. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ.
    Gynecol Oncol; 2006 Jan 01; 100(1):58-64. PubMed ID: 16137750
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group.
    N Engl J Med; 2002 May 23; 346(21):1616-22. PubMed ID: 12023993
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
    McEwen AR, McConnell DT, Kenwright DN, Gaskell DJ, Cherry A, Kidd AM.
    Gynecol Oncol; 2004 Mar 23; 92(3):992-4. PubMed ID: 14984974
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM, Rebbeck TR.
    Curr Opin Obstet Gynecol; 2007 Feb 23; 19(1):27-30. PubMed ID: 17218848
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group.
    JAMA; 2006 Jul 12; 296(2):185-92. PubMed ID: 16835424
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.
    Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, Vennin P.
    Gynecol Oncol; 2011 Jun 01; 121(3):472-6. PubMed ID: 21411127
    [Abstract] [Full Text] [Related]

  • 20. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
    Cancer; 2006 Dec 15; 107(12):2745-51. PubMed ID: 17109443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.